May 4, 2018, Reno, NV. Expanded Go-To-Market Team

2 weeks 5 days ago
Cyrcadia, Inc. is pleased to announce the addition of Marly Heidkamp, Chief Operating Officer, R.N., MSEd to the executive team to focus on execution of the Go-to- Market plan. Jim Holmes, CFO, say, “We are pleased to have an operations executive join our team who possesses medical product management experience as well. We are confident […]

April 30, 2018, Reno, NV. Clinical Trial Resumption Update

3 weeks 2 days ago
As Cyrcadia prepares to move to clinical markets, Matt Benardis, CEO; Jim Holmes, CFO; along with our Clinical Research associate (CRA) met with clinical trial investigators and administration at El Camino Hospital, in San Mateo, CA, to discuss previous participant follow-up and trial resumption with our modified clinical product and associated study protocol. Do note […]

Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter

3 months ago
February 27, 2018 Cyrcadia, Inc. (“CI”) extends its thanks and appreciation in your interest and support of our endeavors. We are taking this opportunity to provide an update, as well as apprise you of upcoming expectations. License and Cooperation Agreement with Cyrcadia Asia (“CA”) – Status Earlier in 2017 CI entered into an Agreement with […]

Cyrcadia, Inc. Wins Prestigious Cannes Lions Awards

9 months 4 weeks ago
Cyrcadia, Inc. (CI) announced it has won two prestigious awards at the Cannes Lions International Festival of Creativity, a global event for the creative communications, marketing and advertising world. Held in Cannes, France and attended by over 10,000 delegates, Lion awards are considered the most coveted in the industry. The first award was a Bronze […]

Lifeline announces transfer of breast cancer detection technology to subsidiary

10 months 3 weeks ago
Reno-based Lifeline Biotechnologies, Inc. (OTC PINK: LLBO) recently transferred breast cancer detection technology to Cyrcadia, Inc. in exchange for 4,670,000 shares of Cyrcadia, Inc. common stock and a $110,000 cash and $220,000 promissory note. The additional 4,670,000 shares added to Lifeline’s original 8,000,000 shares totals 12,670,000 shares. Lifeline’s ownership is increased to over 45 percent of Cyrcadia, Inc., making Lifeline Cyrcadia, Inc.’s […]

Sports Business Advisor Mandy Antoniacci Joins Cyrcadia Health

1 year 11 months ago
CYRCADIA HEALTH EXPANDS ADVISORY BOARD WITH NATIONALLY RECOGNIZED AUTHOR AND SPORTS BUSINESS ADVISOR MANDY ANTONIACCI Magazine Columnist, Sports Business Advisor and Advocate for Social Change Fills Key Position for Cyrcadia Reno, Nev. – June 2, 2016 – Cyrcadia Health, awarded the 2016 Gold Edison Award as Top Healthcare Wearable for its early breast cancer screening technology, is […]
Rob Royea

“‘iTBra’ Could Be the Key to Early Breast Cancer Detection”

2 years ago
Cyrcadia’s technology was recently featured and Columbus, Ohio’s WBNS-TV10, notifying the viewing public of the expansion of our clinical trials at The Ohio State University.  We are pleased to have Dr. William Farrar’s support in this endeavor.  Please have a look. ‘iTBra’ could be the key to early breast cancer detection.  
Matt Benardis

The human element of IoE changing the way breast cancer is detected.

2 years 6 months ago
Vatsun Thirapatarapong November 3, 2015 8:47 am In Thailand, breast cancer is the number-one cancer killing women, averaging seven women dying per week. More than 19 million Thai women are now in risk of having breast cancer. Such statistics on the occurrence of breast cancer are terrifying, but incredible strides across all forms of cancer […]
Matt Benardis
1 week 2 days ago
Early Detection Technology for Breast Cancer
Subscribe to News feed

About Lifeline Biotechnologies:
Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in 1994 is based in Reno, NV.  LLBO has invested over $10M in a device and process for early detection of breast tissue abnormalities some of which are cancerous or pre-cancer.  Three “Proof of Concept” clinical trials of over 500 women have been completed and three patents (one hardware, two software) have been awarded. 

Safe Harbor:
This publication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.